This article is from the source 'rtcom' and was first published or seen on . The next check for changes will be

You can find the current article at its original source at https://www.rt.com/news/524954-china-sinopharm-vaccines-efficacy/

The article has changed 3 times. There is an RSS feed of changes available.

Version 1 Version 2
Sinopharm data on Covid-19 vaccines shows efficacy above 70% but little data on elderly or vulnerable Sinopharm data on Covid-19 vaccines shows efficacy above 70% but little data on elderly or vulnerable
(about 1 month later)
A study published in an American medical journal has shown that Sinopharm’s two jabs are 72.8% and 78.1% effective at preventing symptomatic Covid-19, but says there is insufficient trial data from elderly and vulnerable groups.A study published in an American medical journal has shown that Sinopharm’s two jabs are 72.8% and 78.1% effective at preventing symptomatic Covid-19, but says there is insufficient trial data from elderly and vulnerable groups.
The study, published in the Journal of the American Medical Association on Wednesday, shows the two Chinese-made shots to be more effective than the World Health Organization (WHO) minimum requirement of 50% efficacy. The study references interim data from phase-3 trials involving 40,832 volunteers from across the UAE, Bahrain, Egypt and Jordan.The study, published in the Journal of the American Medical Association on Wednesday, shows the two Chinese-made shots to be more effective than the World Health Organization (WHO) minimum requirement of 50% efficacy. The study references interim data from phase-3 trials involving 40,832 volunteers from across the UAE, Bahrain, Egypt and Jordan.
The published data answers scientists’ calls for greater transparency about the shots that have been administered more than 200 million times around the world.The published data answers scientists’ calls for greater transparency about the shots that have been administered more than 200 million times around the world.
The trial data show the vaccine made by Sinopharm’s Beijing subsidiary, which has already been approved by the WHO, to be 78.1% effective in preventing symptomatic Covid-19.The trial data show the vaccine made by Sinopharm’s Beijing subsidiary, which has already been approved by the WHO, to be 78.1% effective in preventing symptomatic Covid-19.
The efficacy drops to 73.5% when asymptomatic cases are taken into account. The shot made by Sinopharm’s Wuhan subsidiary is seemingly less effective, demonstrating 72.8% efficacy against symptomatic cases and 64% when asymptomatic infections are included. The efficacy drops to 73.5% when asymptomatic cases are taken into account. The shot made by Sinopharm’s Wuhan subsidiary is seemingly less effective, demonstrating 72.8% efficacy against symptomatic cases and 64% when asymptomatic infections are included. 
However, there are concerns that the vaccine has not been properly trialed on elderly and vulnerable groups. Approximately 600 people over 60 were recruited for the trial with some receiving a placebo. The study notes: “No incident cases of Covid-19 occurred in either group, thus efficacy was not calculated.”However, there are concerns that the vaccine has not been properly trialed on elderly and vulnerable groups. Approximately 600 people over 60 were recruited for the trial with some receiving a placebo. The study notes: “No incident cases of Covid-19 occurred in either group, thus efficacy was not calculated.”
The authors note further limitations to the study, including that the jabs weren’t tested on pregnant women or those younger than 18 years and that “the trial was mainly conducted in generally healthy, young men in the Middle East.” They add that the trial is ongoing, and that further study is needed to “refine long-term efficacy estimates.”The authors note further limitations to the study, including that the jabs weren’t tested on pregnant women or those younger than 18 years and that “the trial was mainly conducted in generally healthy, young men in the Middle East.” They add that the trial is ongoing, and that further study is needed to “refine long-term efficacy estimates.”
The publication comes amid concern about the effectiveness of Chinese vaccines despite the WHO’s decision to grant emergency approval to Sinopharm shot from its Beijing subsidiary.The publication comes amid concern about the effectiveness of Chinese vaccines despite the WHO’s decision to grant emergency approval to Sinopharm shot from its Beijing subsidiary.
If you like this story, share it with a friend!If you like this story, share it with a friend!
Dear readers and commenters,
We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.
Sorry for the inconvenience, and looking forward to your future comments,
RT Team.